Literature DB >> 8614135

Effective control of pulmonary vascular resistance with inhaled nitric oxide after cardiac operation.

D A Fullerton1, S D Jones, J Jaggers, F Piedalue, F L Grover, R C McIntyre.   

Abstract

Increased pulmonary vascular resistance may greatly complicate the perioperative management of cardiac surgical patients. Inhaled nitric oxide may be a promising new therapy to selectively lower pulmonary vascular resistance. The purpose of this study was to examine the effects of inhaled nitric oxide on pulmonary and systemic hemodynamics in cardiac surgical patients. Twenty patients (age 57 +/- 6 years) were studied in the operating room after weaning from cardiopulmonary bypass. Mean pulmonary artery pressure, pulmonary vascular resistance, systemic vascular resistance, and mean aortic pressure were determined at four points of data collection: before nitric oxide, with 20 ppm nitric oxide, with 40 ppm nitric oxide, and after nitric oxide. Statistical analysis was by analysis of variance; significance was accepted for p < 0.05. Inhaled nitric oxide produced selective pulmonary vasorelaxation. Pulmonary vascular resistance was lowered from 343 +/- 30 before nitric oxide to 233 +/- 25 dynes.sec-1.cm-5 with 20 ppm nitric oxide. Pulmonary vascular resistance was not further lowered by 40 ppm nitric oxide (p < 0.05). Mean pulmonary arterial pressure was 29 +/- 1 mm Hg before nitric oxide and was lowered to 22 +/- 1 mm Hg by 20 ppm nitric oxide and 21 +/- 1 mm Hg by 40 ppm nitric oxide (p < 0.05). Both pulmonary vascular resistance and mean pulmonary arterial pressure returned to baseline after withdrawal of inhaled nitric oxide. Inhaled nitric oxide produced no changes in either systemic vascular resistance or mean aortic pressure. We conclude that nitric oxide may be used as an effective pulmonary vasodilator after cardiac operations. It may be particularly valuable for selectively lowering right ventricular afterload in patients with right ventricular dysfunction.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8614135     DOI: 10.1016/s0022-5223(96)70335-5

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  6 in total

Review 1.  Review of inhaled nitric oxide in the pediatric cardiac surgery setting.

Authors:  Paul A Checchia; Ronald A Bronicki; Brahm Goldstein
Journal:  Pediatr Cardiol       Date:  2012-04       Impact factor: 1.655

2.  Effects of a localized high-flow anastomosis between the aorta and left lower lobe pulmonary artery on great vessel flow and pulmonary arterial reactivity in the contralateral lung.

Authors:  Lewis Somberg; Ram Nirula; Michael Bousamra; Jill Friesema; Daling Zhu; Meetha Medhora; Elizabeth R Jacobs
Journal:  J Thorac Cardiovasc Surg       Date:  2010-11-13       Impact factor: 5.209

3.  Inhaled nitric oxide therapy in adults: European expert recommendations.

Authors:  Peter Germann; Antonio Braschi; Giorgio Della Rocca; Anh Tuan Dinh-Xuan; Konrad Falke; Claes Frostell; Lars E Gustafsson; Philippe Hervé; Philippe Jolliet; Udo Kaisers; Hector Litvan; Duncan J Macrae; Marco Maggiorini; Nandor Marczin; Bernd Mueller; Didier Payen; Marco Ranucci; Dietmar Schranz; Rainer Zimmermann; Roman Ullrich
Journal:  Intensive Care Med       Date:  2005-06-23       Impact factor: 17.440

4.  S3 guidelines for intensive care in cardiac surgery patients: hemodynamic monitoring and cardiocirculary system.

Authors:  M Carl; A Alms; J Braun; A Dongas; J Erb; A Goetz; M Goepfert; W Gogarten; J Grosse; A R Heller; M Heringlake; M Kastrup; A Kroener; S A Loer; G Marggraf; A Markewitz; D Reuter; D V Schmitt; U Schirmer; C Wiesenack; B Zwissler; C Spies
Journal:  Ger Med Sci       Date:  2010-06-15

Review 5.  Inhaled NO as a therapeutic agent.

Authors:  Kenneth D Bloch; Fumito Ichinose; Jesse D Roberts; Warren M Zapol
Journal:  Cardiovasc Res       Date:  2007-05-04       Impact factor: 10.787

6.  Modeling lung perfusion abnormalities to explain early COVID-19 hypoxemia.

Authors:  Jacob Herrmann; Vitor Mori; Jason H T Bates; Béla Suki
Journal:  Nat Commun       Date:  2020-09-28       Impact factor: 14.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.